Skip to main content

Recent News & Research

ResearchTreatments

Patritumab Deruxtecan Granted U.S. FDA Breakthrough Therapy Designation in Patients with Metastatic EGFR-Mutated NSCLC

*December 2021* Note 1: A breakthrough therapy designation is for a drug that treats a serious or life-threatening condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement on a clinically significant endpoint(s) over available therapies. Note 2: This is a potential treatment for EGFR patients after progression with osimertinib…
laurabbook@gmail.com
January 21, 2022
ResearchTreatments

Comparing EGFR tyrosine kinase inhibitor treatments in EGFR-mutated non-small cell lung cancer across Asian and non-Asian patients: a plain language summary

*December 2021* How people from different ethnic populations respond differently to treatments for a type of lung cancer called non-small cell lung cancer (also known as NSCLC). EGFR tyrosine kinase inhibitors (often shortened to EGFR TKI treatments) are a form of treatment for NSCLC called EGFR mutation-positive NSCLC. There are currently…
laurabbook@gmail.com
January 21, 2022
ResearchTreatments

New Clinical Trials

*January 2022* A Phase 1/2 Study of the Highly Selective EGFR Inhibitor, BLU-701, in Patients With EGFR-Mutant Non-Small Cell Lung Cancer BLU-701 is a highly potent, brain-penetrant and WT-sparing next-generation EGFR TKI for the treatment of sensitizing (ex19del, L858R) and C797S resistance mutations in metastatic NSCLC WSD0922-FU for the Treatment…
laurabbook@gmail.com
January 21, 2022
ResearchTreatments

Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: final analysis of the GioTag study

*August 2020* The GioTag study assessed how drugs called afatinib and osimertinib affected people with non-small cell lung cancer (NSCLC) who had mutations in the epidermal growth factor receptor (EGFR) gene. Resistance mutations in our genes can lead to resistance to specific treatments, meaning that drugs no longer work. Patients…
laurabbook@gmail.com
December 8, 2021
ResearchTreatments

EGFR Combination Therapy Should Become the New Standard First-Line Treatment in Advanced EGFR-Mutant NSCLC

*October 2021* The discovery of the EGFR driver mutation, and the subsequent development of EGFR-targeted therapy, has drastically changed the treatment and prognosis of this subgroup of patients with metastatic NSCLC. More recently, targeted therapy is also changing the treatment paradigm and outcomes for patients with early stage disease.1 Although…
laurabbook@gmail.com
December 8, 2021
ResearchTreatments

Dr. Brahmer on the Utility of Consolidative Immunotherapy Vs Targeted Therapy in NSCLC

*November 2021* Julie Renee Brahmer, MD, MSc, professor of oncology, co-director, Upper Aerodigestive Department, Bloomberg~Kimmel Institute for Cancer Immunotherapy, co-director, Cancer Immunology Program, director, Thoracic Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medicine, discusses questions regarding the role of consolidative immunotherapy vs targeted therapy in locally advanced non–small cell…
laurabbook@gmail.com
December 8, 2021
ResearchTreatments

Genomic signatures define three subtypes of EGFR-mutant stage II–III non-small-cell lung cancer with distinct adjuvant therapy outcomes

*November 2021* The ADJUVANT study reported the comparative superiority of adjuvant gefitinib over chemotherapy in disease-free survival of resected EGFR-mutant stage II–IIIA non-small cell lung cancer (NSCLC). However, not all patients experienced favorable clinical outcomes with tyrosine kinase inhibitors (TKI), raising the necessity for further biomarker assessment. In this work, by…
laurabbook@gmail.com
December 8, 2021
ResearchTreatments

Treating disease progression with osimertinib in EGFR-mutated non-small-cell lung cancer: novel targeted agents and combination strategies

*October 2021* Highlights Acquired resistance mechanisms to osimertinib can be EGFR dependent or independent. First- and fourth-generation EGFR-TKIs are able to overcome EGFR-dependent resistance. MET and MEK inhibitors may overcome EGFR-independent resistance. Anti-HER/MET novel monoclonal antibody seems effective across multiple resistance mechanisms. Carboplatin/paclitaxel ± bevacizumab/atezolizumab represents a feasible option in…
laurabbook@gmail.com
December 8, 2021